Contraindications can damage your health--is metformin a case in point?
about
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Metformin for obesity or overweightMetformin for obesity or overweightEffect of prescribing metformin according to eGFR instead of serum creatinine level: A study based on Korean National Health and Nutrition Examination Survey (KNHANES) 2009-2014.Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? YesHow are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA studyEffects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention--a retrospective nationwide cohort studyClinical evaluation of Dyslipidemia among type II diabetic patients at Public hospital Penang, Malaysia.Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options.Outcome of severe lactic acidosis associated with metformin accumulation.Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients.Impact of metformin use on the prognostic value of lactate in sepsis.Inpatient treatment of type 2 diabetes.Potential Impact of Prescribing Metformin According to eGFR Rather Than Serum Creatinine.Effect of concomitant administration of trospium chloride extended release on the steady-state pharmacokinetics of metformin in healthy adults.The safety of metformin in heart failure.Metformin therapy and clinical uses.Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.Hypoxic pulmonary vasoconstriction: mechanisms of oxygen-sensing.Oral anti-diabetic drugs for the prevention of Type 2 diabetes.Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.Pathophysiology, prevention and management of chronic kidney disease in the hypertensive patient with diabetes mellitus.Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines.Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis.The older patient with diabetes: a practical approach.Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial.Metformin Safety Warnings and Diabetes Drug Prescribing Patterns for Older Nursing Home Residents.Lactic acidosis: relationship between metformin levels, lactate concentration and mortality.Impact of Japanese regulatory action on metformin-associated lactic acidosis in type II diabetes patients.Metformin: diamonds are forever.Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version : JSN, JRS, and JCS Joint Working Group.Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version. JSN, JRS, and JCS Joint Working Group.Metformin and lactic acidosis in patients with type 2 diabetes--from pride and prejudice to sense and sensibility.Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min).Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Metformin usage in type 2 diabetes mellitus: are safety guidelines adhered to?
P2860
Q22241288-E86E7DA0-6220-457B-B92F-0660183C59BCQ24195145-C431E118-31D5-4197-A5A6-9AAE5CB441CFQ24236796-691CF0FA-857C-49CA-BF8F-71C0D8E672BBQ33554434-A4694960-7C44-43E8-BC3B-349818762D62Q33610682-D1C66E87-D87E-483D-8D97-8D5F844A6581Q33779315-1E10439D-7B53-4CA8-AC90-11E104977979Q34158078-941F1029-FEF6-4376-85BE-1EB002D00DA6Q34410378-084AEE69-28EA-4465-A483-12CB49FEA7CBQ34563587-ACA020BC-3129-4C9A-A63C-046261E2EC2CQ35561308-086C47FF-85AD-4843-BDF7-326583913E96Q35684836-77D2902D-D864-471F-83FB-FDEB45866A0FQ36049464-111489FB-E574-446C-AC4F-4D101D4358A5Q36108287-A0298E6E-08B8-44B6-8851-E84A6EE38808Q36185994-0C734567-ED79-4510-B87D-BD55BE7F77CCQ36579750-CC6AE01C-A648-42B3-B400-B9E89FB22F88Q36765255-AF09E622-107D-40A0-9578-A88C376CC0F3Q37262966-07EC26A1-F2F0-4F04-AA92-FC1FD40784B5Q37779779-E0EFAC6B-2E1D-4F84-ADA6-3400A48E51BDQ37820834-A68D6CBA-6289-4462-93E1-B40EFB471898Q37856436-53179CF8-6853-4E65-B006-FAD3F3EA1450Q37858364-2C1B0232-D435-4553-AF77-D96123E01926Q37861885-F9D5221A-32E3-4A49-A384-96BCFB8465D5Q37922124-DC7E8AB9-6677-41CF-A13A-5533570CA9A9Q37982112-FEA31EB3-0658-490C-B72A-8A4570522542Q38012068-0EFA979F-94FE-4B7E-B3B2-00B41940F2ECQ38086611-4BCD71D5-F89C-4343-9076-739B924DD404Q38095393-E01C2DD3-0276-4310-A274-B056B50C6F33Q38152414-173F3E24-6E9E-469A-BC38-A41DC1AB9EFBQ38410465-57C69971-C4F6-4DB4-B4A0-76DC414DF137Q38694106-BC80150C-8F91-4E4D-9383-20C62520DB1AQ39993479-CB9AD9C1-7DD5-4FFF-8045-A68EAC8E9A91Q41141739-7073F660-1635-47D3-AA85-D9756595E502Q43292535-AE5D169D-3328-40D7-94FE-820D08366F94Q45043102-A0190E95-4F29-4C0E-AA5C-7759AE8AE1ADQ45334831-BFCBDD5E-4A09-44B7-A498-F38EFB601CCAQ46076997-1A78A9A1-5B37-40C1-A7B5-F91C9CF59A05Q50798695-B57536F8-ABEF-40CE-942F-AF6FCFE8F384Q53519441-65C8B9FA-E5AD-407D-8C36-F8AF1345866BQ57412648-448DDA85-F320-4BF6-9A92-BD5C3B55C0BCQ58804919-DBE9CEC9-F25B-4406-93ED-9FA70DF00F81
P2860
Contraindications can damage your health--is metformin a case in point?
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Contraindications can damage your health--is metformin a case in point?
@ast
Contraindications can damage your health--is metformin a case in point?
@en
Contraindications can damage your health--is metformin a case in point?
@nl
type
label
Contraindications can damage your health--is metformin a case in point?
@ast
Contraindications can damage your health--is metformin a case in point?
@en
Contraindications can damage your health--is metformin a case in point?
@nl
prefLabel
Contraindications can damage your health--is metformin a case in point?
@ast
Contraindications can damage your health--is metformin a case in point?
@en
Contraindications can damage your health--is metformin a case in point?
@nl
P1433
P1476
Contraindications can damage your health--is metformin a case in point?
@en
P2093
Holstein A
P2888
P304
P356
10.1007/S00125-005-0026-1
P577
2005-11-11T00:00:00Z
P5875
P6179
1015482487